Share on StockTwits

Amicus Therapeutics (NASDAQ:FOLD) Director Glenn Sblendorio sold 10,000 shares of the stock on the open market in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $6.50, for a total transaction of $65,000.00. Following the completion of the sale, the director now directly owns 11,933 shares of the company’s stock, valued at approximately $77,565. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Amicus Therapeutics (NASDAQ:FOLD) traded down 1.10% during mid-day trading on Friday, hitting $7.19. The stock had a trading volume of 6,555,771 shares. Amicus Therapeutics has a 52-week low of $1.77 and a 52-week high of $7.52. The stock’s 50-day moving average is $4.63 and its 200-day moving average is $3.02. The company’s market cap is $565.9 million.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.08. On average, analysts predict that Amicus Therapeutics will post $-0.94 earnings per share for the current fiscal year.

A number of research firms have recently commented on FOLD. Analysts at Cowen and Company raised their price target on shares of Amicus Therapeutics to $14.00 in a research note on Wednesday, August 20th. Separately, analysts at Janney Montgomery Scott upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 1st. They now have a $5.00 price target on the stock, up previously from $2.50. Finally, analysts at Leerink Swann upgraded shares of Amicus Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 1st. They now have a $6.00 price target on the stock, up previously from $2.50.

Amicus Therapeutics, Inc (NASDAQ:FOLD) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.